Economics Of Harm From Biologic-Biosimilar Competition
For more than two decades and despite the Biologics Price Competition and Innovation Act of 2009, the Hatch-Waxman brand-generic disputes have dominated the life sciences competitive landscape. However, a new and...To view the full article, register now.
Already a subscriber? Click here to view full article